Scotland’s Patient Safety Programme Makes a Commitment to the Patient Safety Movement Foundation
The Patient Safety Movement Foundation (PSMF) announced today a commitment from Scotland’s national patient safety initiative, the Scottish Patient Safety Programme (SPSP).
Launched in 2008, the SPSP first started as a five-year program focused on acute hospitals and now operates as a national initiative managed by Healthcare Improvement Scotland aimed at improving the safety and reliability of healthcare, whenever care is delivered.
SPSP’s commitment through the Patient Safety Movement Foundation is broken down into the 6 different areas listed below. Central to all of the areas are three core themes: 1) Prevention, recognition and response to deterioration 2) Medicines Safety and 3) System enablers. For complete details, please visit their commitment online.
- Acute Adult: Improving reliable care delivery, communication and care planning & reducing harm and mortality in hospitals
- Hospital Acquired Infections (HAIs): Application of standard infection control precautions (SICPs) in all care settings & achieving reliable systems and processes around the reduction of HAIs
- Primary Care: Improving safety across the community and across the interface & reducing harm from high risk medicines
- Maternity and Children (includes pediatric and neonatal care): Improving outcomes for babies, children and their mothers & increasing women’s satisfaction of their experience of care
Medication: Taking a whole system
approach to the safer use of medicines
& optimizing medication reconciliation and reducing harm from high risk medicines
- Mental Health: Improving risk assessment and safety planning & reducing harm from restraint and seclusion
The programme’s goals include:
- Improving patient safety in acute care by ensuring 95% of people are free from harm in the following areas: Cardiac Arrest, Catheter-associated Urinary Tract Infection (CAUTI), pressure ulcers and falls
- Reducing the hospital-standardized mortality ratio (HSMR) by 20%
- Increasing the percentage of women satisfied with their experience of maternity care to >95%
- Reducing the incidence of avoidable harm in women and babies by 30%
- Reducing stillbirths and neonatal mortality by 15%
- Reducing severe post-partum haemorrhage (PPH) by 30%
- Reducing the incidence of non-medically indicated elective deliveries prior to 39 weeks gestation by 30%
- General Dental Practice Teams plan to achieve 90% compliance with high risk medications care bundle by December 2016
- 50% of Primary Care Clinical Teams plan to complete a Safety Climate Survey and develop their safety culture by March 2017
- Reducing pressure ulcers in care homes by 50% by December 2017
- Ensuring that within Mental Health inpatient units, both the patients and staff are kept safe and feel safe
“We are excited to be working with the Patient Safety Movement Foundation,” said Joanne Matthews, Head of the SPSP. “Our programme has to date been delivered through a collaborative approach based on the Breakthrough Series Collaborative Model, using national and local learning events, site visits , webinars, collecting data and sharing learning across the country. With ongoing programme expansion and development, a range of other improvement methods are now being tested.”
“We are impressed with Scotland’s Patient Safety program and their government’s focus on making patient safety a top priority,” said Joe Kiani, Founder of the Patient Safety Movement Foundation “Patient safety is a global issue and we hope to assist in breaking down the silos in the healthcare eco-system around the world. We can help each other move towards attaining zero faster.”
About The Patient Safety Movement Foundation
More than 3,000,000 people worldwide, and 200,000 people in the US die every year in hospitals in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare, to reduce that number of preventable deaths to 0 by 2020 (0X2020) in the US and dramatically worldwide. Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems and solutions of patient safety. The Foundation also convenes the annual World Patient Safety, Science and Technology summit. The Summit presents specific, actionable solutions to meet patient safety challenges, encouraging medical technology companies to share the data for which their products are purchased, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions. Visit www.patientsafetymovement.org.
@0x2020 #patientsafety #0x2020
The Patient Safety Movement Foundation
Irene Paigah, 858-859-7001
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on